A case of fibrosing interstitial pneumonia
DOI:
https://doi.org/10.6092/1828-6550/APMB.108.1.2020.CCS1Keywords:
amiodarone, pulmonary toxicity, interstitiallung disease, pulmonary fibrosisAbstract
We report here the case of a 70 year-old male, lifelong never smoker, who has been admitted to our inpatient Pulmonology clinic for the presence by one month of persistent fever associated in the last seven days with fatigue and mild exertional dyspnea (2 at the Borg scale). An arterial blood gas analysis performed during oxygen therapy [fractional concentration of oxygen in inspired gas (FiO2) of 40%] showed the presence of an acute hypoxemic respiratory failure. He had a past medical history of paroxysmal atrial fibrillation treated in the last two years with low-dose amiodarone and edoxaban. High-resolution computed tomography of the chest showed a bilateral, but with the prevalence in the right lung, pattern of interstitial lung disease with diffuse ground glass opacities with high attenuation, interstitial thickening, traction bronchiectasis and honeycombing. A diagnosis of amiodarone-induced pulmonary fibrosis was done and the drug was stopped and replaced with bisoprolol and concomitant treatment with systemic glucocorticoids for two weeks was started. The patient was discharged at home without respiratory failure. The patient died five months later in the Pulmonology clinic “Vittorio Emanuele” University Hospital of Catania, Italy during another acute exacerbation of its disease.
Our report is a reminder for clinicians to recognize that even low-dose amiodarone (200 mg/daily) may be associated with severe pulmonary fibrosis. There is a complete absence of a standardized approach to the diagnosis and treatment of this disease.References
1. Schwaiblmair, M., Berghaus, T. (2010). Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect? Clin Res Cardiol. 99(11), 693-700.doi: 10.1007/s00392-010-0181-3.
2. Wolkove, N., Baltzan, M. (2009). Amiodarone Pulmonary Toxicity. Can Respir J. 16(2), 43-48. doi./10.1155/2009/282540
3. Stewart, J.I., Chawla, R. (2008). Amiodarone Pneumonitis. Respir Care. 53(3), 370-375.
4. Yamada, Y., Shiga, T., Matsuda, N., Hagiwara, N., Kasanuki, H. (2007). Incidende and predictors of pulmonary toxicity in japanese patients receiving low-dose amiodarone. Circ J. 71(10), 1610-1616. Doi:10.1253/cirj
5. Polkey, M.I., Wilson, P.O., Rees, P.J.(1995). Amiodarone pneumonitis: no safe dose. RespirMed. 89(3), 233-235. doi:10.1016/0954-6111(95)90254-6
6. Nacca, N., Bhamidipati, C.M. (2012). Severe amiodarone induced pulmonary toxicity. J Thorac Dis. 4(6), 667-670.doi: 10.3978/j.issn.2072-1439
7. Mankikian, J., Favelle, O., Guillon, A., Guilleminault, L., Cormier, B., Jonville-Bera, A.P., Perrotin, D., Diot, P., Marchand-Adam, S. (2014). Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity. Respir Med. 108(4), 638-646.doi: 10.1016/j.rmed.2014
Bellanti, M.T., Coppolino, I., Proietto, A., Picciolo, S., Relo, R., Chillè, G., Salamone, I., Ruggeri, P., Caramori, G. (2019). A patient with acute hypoxemic respiratory failure and diffuse alveolar hemorrhage syndrome. APMB. 107(2),1-4 doi:10.6092/1828-6550
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
